Concepts (142)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tissue and Organ Procurement | 8 | 2022 | 243 | 3.040 |
Why?
|
| Liver Transplantation | 22 | 2024 | 1187 | 2.690 |
Why?
|
| Tissue Donors | 14 | 2022 | 819 | 2.240 |
Why?
|
| Organ Transplantation | 4 | 2020 | 210 | 1.800 |
Why?
|
| Kidney Transplantation | 7 | 2022 | 750 | 1.410 |
Why?
|
| Donor Selection | 3 | 2020 | 110 | 1.400 |
Why?
|
| Thrombosis | 3 | 2022 | 742 | 1.120 |
Why?
|
| Transplant Recipients | 5 | 2022 | 335 | 0.910 |
Why?
|
| Kidney Failure, Chronic | 4 | 2021 | 931 | 0.880 |
Why?
|
| Graft Rejection | 4 | 2020 | 844 | 0.850 |
Why?
|
| Death | 2 | 2021 | 129 | 0.820 |
Why?
|
| Venous Thrombosis | 2 | 2022 | 380 | 0.750 |
Why?
|
| Waiting Lists | 6 | 2024 | 267 | 0.690 |
Why?
|
| Health Care Rationing | 1 | 2020 | 80 | 0.680 |
Why?
|
| Graft Survival | 10 | 2022 | 1076 | 0.610 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2019 | 143 | 0.600 |
Why?
|
| Vena Cava, Inferior | 1 | 2019 | 193 | 0.600 |
Why?
|
| Liver Diseases | 1 | 2022 | 599 | 0.550 |
Why?
|
| End Stage Liver Disease | 5 | 2024 | 189 | 0.550 |
Why?
|
| Perioperative Care | 1 | 2020 | 448 | 0.540 |
Why?
|
| Immunocompromised Host | 1 | 2020 | 718 | 0.520 |
Why?
|
| Betacoronavirus | 1 | 2020 | 514 | 0.490 |
Why?
|
| Pandemics | 2 | 2020 | 1608 | 0.460 |
Why?
|
| Portal Vein | 3 | 2022 | 363 | 0.460 |
Why?
|
| Immunosuppressive Agents | 1 | 2020 | 1436 | 0.460 |
Why?
|
| Health Services Accessibility | 1 | 2020 | 819 | 0.460 |
Why?
|
| Patient Selection | 1 | 2020 | 2028 | 0.410 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 623 | 0.410 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 701 | 0.410 |
Why?
|
| Registries | 1 | 2019 | 2209 | 0.360 |
Why?
|
| Length of Stay | 5 | 2021 | 1997 | 0.340 |
Why?
|
| Iliac Vein | 2 | 2019 | 41 | 0.320 |
Why?
|
| Vascular Grafting | 2 | 2019 | 46 | 0.320 |
Why?
|
| Child | 20 | 2024 | 30558 | 0.310 |
Why?
|
| Biliary Atresia | 2 | 2023 | 206 | 0.300 |
Why?
|
| Allografts | 5 | 2021 | 686 | 0.290 |
Why?
|
| Child, Preschool | 13 | 2024 | 17075 | 0.250 |
Why?
|
| Humans | 39 | 2024 | 270601 | 0.240 |
Why?
|
| Adolescent | 14 | 2024 | 32684 | 0.240 |
Why?
|
| Decision Support Techniques | 2 | 2019 | 603 | 0.220 |
Why?
|
| Retrospective Studies | 21 | 2024 | 39922 | 0.210 |
Why?
|
| Adenovirus Infections, Human | 1 | 2023 | 55 | 0.210 |
Why?
|
| Infant | 11 | 2024 | 13992 | 0.200 |
Why?
|
| Liver Failure, Acute | 1 | 2023 | 98 | 0.190 |
Why?
|
| Catheters | 1 | 2022 | 133 | 0.190 |
Why?
|
| Risk Factors | 14 | 2024 | 17855 | 0.190 |
Why?
|
| Hepatic Artery | 1 | 2022 | 255 | 0.180 |
Why?
|
| Hepatoblastoma | 1 | 2023 | 223 | 0.180 |
Why?
|
| Postoperative Period | 2 | 2020 | 666 | 0.180 |
Why?
|
| Thrombectomy | 1 | 2021 | 167 | 0.180 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2021 | 161 | 0.180 |
Why?
|
| Respiration, Artificial | 1 | 2023 | 585 | 0.170 |
Why?
|
| Twins, Conjoined | 1 | 2020 | 30 | 0.170 |
Why?
|
| Public Opinion | 1 | 2020 | 74 | 0.170 |
Why?
|
| Gastroenteritis | 1 | 2023 | 350 | 0.170 |
Why?
|
| Hospitalization | 2 | 2020 | 2170 | 0.170 |
Why?
|
| Treatment Outcome | 11 | 2023 | 33811 | 0.170 |
Why?
|
| Learning Curve | 1 | 2020 | 79 | 0.170 |
Why?
|
| Attitude | 1 | 2020 | 161 | 0.170 |
Why?
|
| Renal Veins | 1 | 2019 | 63 | 0.170 |
Why?
|
| Models, Anatomic | 1 | 2020 | 144 | 0.160 |
Why?
|
| Directed Tissue Donation | 1 | 2019 | 6 | 0.160 |
Why?
|
| Tetrazoles | 1 | 2019 | 96 | 0.160 |
Why?
|
| Severity of Illness Index | 2 | 2020 | 4391 | 0.160 |
Why?
|
| Infant, Newborn | 6 | 2024 | 8602 | 0.160 |
Why?
|
| Printing, Three-Dimensional | 1 | 2020 | 144 | 0.160 |
Why?
|
| Cold Ischemia | 1 | 2018 | 22 | 0.150 |
Why?
|
| Age Factors | 6 | 2021 | 5441 | 0.150 |
Why?
|
| Cardiomyopathies | 1 | 2023 | 548 | 0.150 |
Why?
|
| Clinical Protocols | 1 | 2020 | 477 | 0.150 |
Why?
|
| Male | 20 | 2024 | 128395 | 0.150 |
Why?
|
| Anastomosis, Surgical | 1 | 2019 | 370 | 0.150 |
Why?
|
| Blood Loss, Surgical | 1 | 2019 | 295 | 0.140 |
Why?
|
| Erythrocyte Transfusion | 1 | 2019 | 207 | 0.140 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2018 | 126 | 0.140 |
Why?
|
| Liver Failure | 1 | 2017 | 137 | 0.140 |
Why?
|
| Anticoagulants | 1 | 2022 | 777 | 0.130 |
Why?
|
| Liver Cirrhosis, Biliary | 1 | 2016 | 87 | 0.130 |
Why?
|
| Blood Group Incompatibility | 1 | 2016 | 39 | 0.130 |
Why?
|
| ABO Blood-Group System | 1 | 2016 | 125 | 0.130 |
Why?
|
| Aorta | 1 | 2019 | 666 | 0.120 |
Why?
|
| Heart Transplantation | 1 | 2022 | 898 | 0.120 |
Why?
|
| Kidney | 2 | 2022 | 2102 | 0.120 |
Why?
|
| Quality Improvement | 1 | 2021 | 911 | 0.120 |
Why?
|
| Critical Care | 2 | 2017 | 794 | 0.110 |
Why?
|
| Reoperation | 1 | 2018 | 1389 | 0.110 |
Why?
|
| Imidazoles | 1 | 2019 | 1065 | 0.110 |
Why?
|
| Body Weight | 2 | 2019 | 1287 | 0.100 |
Why?
|
| Female | 18 | 2024 | 148790 | 0.100 |
Why?
|
| Models, Statistical | 1 | 2017 | 1186 | 0.100 |
Why?
|
| United States | 5 | 2020 | 15827 | 0.090 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2023 | 2189 | 0.090 |
Why?
|
| Cross-Sectional Studies | 1 | 2020 | 4493 | 0.090 |
Why?
|
| Liver | 4 | 2020 | 3056 | 0.080 |
Why?
|
| Pediatrics | 1 | 2019 | 1194 | 0.080 |
Why?
|
| Logistic Models | 3 | 2024 | 3429 | 0.080 |
Why?
|
| Adult | 10 | 2022 | 81960 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2021 | 6257 | 0.080 |
Why?
|
| Proportional Hazards Models | 4 | 2019 | 5099 | 0.070 |
Why?
|
| Transplantation, Homologous | 3 | 2022 | 3048 | 0.070 |
Why?
|
| Follow-Up Studies | 5 | 2022 | 15270 | 0.070 |
Why?
|
| Liver Neoplasms | 1 | 2023 | 4837 | 0.070 |
Why?
|
| Liver Cirrhosis | 2 | 2023 | 1045 | 0.060 |
Why?
|
| Intention to Treat Analysis | 1 | 2024 | 122 | 0.060 |
Why?
|
| Postoperative Complications | 1 | 2018 | 5673 | 0.050 |
Why?
|
| Survival Rate | 3 | 2022 | 12527 | 0.050 |
Why?
|
| GTP-Binding Proteins | 1 | 2023 | 340 | 0.050 |
Why?
|
| Acute Disease | 2 | 2016 | 2492 | 0.050 |
Why?
|
| Protective Factors | 1 | 2021 | 103 | 0.050 |
Why?
|
| Bile Acids and Salts | 1 | 2023 | 270 | 0.050 |
Why?
|
| Predictive Value of Tests | 2 | 2019 | 4964 | 0.040 |
Why?
|
| Middle Aged | 8 | 2020 | 90450 | 0.040 |
Why?
|
| Young Adult | 4 | 2020 | 22219 | 0.040 |
Why?
|
| Prognosis | 3 | 2024 | 22520 | 0.040 |
Why?
|
| Aged | 7 | 2020 | 73534 | 0.040 |
Why?
|
| Operative Time | 1 | 2019 | 253 | 0.040 |
Why?
|
| Health Status Disparities | 1 | 2021 | 321 | 0.040 |
Why?
|
| Intraoperative Care | 1 | 2019 | 272 | 0.040 |
Why?
|
| Adenoviridae | 1 | 2023 | 1490 | 0.040 |
Why?
|
| Risk Assessment | 2 | 2019 | 6762 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2019 | 1562 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 536 | 0.030 |
Why?
|
| Time Factors | 2 | 2019 | 12971 | 0.030 |
Why?
|
| Lymphocytes | 1 | 1999 | 1273 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2016 | 9460 | 0.030 |
Why?
|
| Translocation, Genetic | 1 | 1999 | 1286 | 0.030 |
Why?
|
| Cause of Death | 1 | 2016 | 781 | 0.030 |
Why?
|
| Intensive Care Units | 1 | 2017 | 731 | 0.030 |
Why?
|
| Risk | 1 | 2016 | 1930 | 0.020 |
Why?
|
| Critical Illness | 1 | 2017 | 734 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2018 | 2258 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 4317 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2016 | 2227 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 6193 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 9041 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2016 | 9281 | 0.020 |
Why?
|
| Relative Biological Effectiveness | 1 | 1999 | 227 | 0.010 |
Why?
|
| Temperature | 1 | 1999 | 534 | 0.010 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 1999 | 751 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2016 | 31084 | 0.010 |
Why?
|
| DNA Repair | 1 | 1999 | 1906 | 0.010 |
Why?
|
| DNA Damage | 1 | 1999 | 1991 | 0.010 |
Why?
|